CLINICAL TRIALS PROFILE FOR COLGATE TOTAL

All Clinical Trials for COLGATE TOTAL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01881074 ↗	Periodontal Treatment Response in Type II Diabetic Patients	Completed	Colgate Palmolive		2012-06-01	Diabetes mellitus affects > 171 million people worldwide, with type II diabetes being the most prevalent, affecting 85-95% of the diabetic population. Unfortunately, despite conventional medical treatment, some diabetic patients do not seem to be able to reach desirable metabolic control. This is a double-blinded, randomized study investigating the effects of triclosan containing toothpaste (commercial name: Colgate Total) on the response to periodontal treatment in type II diabetic patients with periodontal disease. The investigators believe that using triclosan containing toothpaste during periodontal treatment will decrease the local inflammatory response and that this reduction will improve periodontal status and metabolic control.
NCT01881074 ↗	Periodontal Treatment Response in Type II Diabetic Patients	Completed	University of Florida		2012-06-01	Diabetes mellitus affects > 171 million people worldwide, with type II diabetes being the most prevalent, affecting 85-95% of the diabetic population. Unfortunately, despite conventional medical treatment, some diabetic patients do not seem to be able to reach desirable metabolic control. This is a double-blinded, randomized study investigating the effects of triclosan containing toothpaste (commercial name: Colgate Total) on the response to periodontal treatment in type II diabetic patients with periodontal disease. The investigators believe that using triclosan containing toothpaste during periodontal treatment will decrease the local inflammatory response and that this reduction will improve periodontal status and metabolic control.
NCT01837199 ↗	MTZ Plus AMX in the Treatment of Smokers and Non-smokers	Completed	University of Guarulhos	Phase 4	2011-07-01	Randomized controlled clinical trials have demonstrated that the use of amoxicillin (AMX) and metronidazole (MTZ) as adjuncts to mechanical therapy improves the clinical and microbiological outcomes of scaling and root planing (SRP) in non-smokers and smokers with ChP. However, the effects of this antibiotic protocol have not been directly compared in non-smokers and smokers. Therefore, the aim of this study will be to compare the clinical and microbiological effects of the adjunctive use of MTZ+AMX to SRP in smokers and non-smokers subjects with chronic periodontitis (ChP). It was hypothesized that non-smokers would benefit better from this combination of therapies than the smokers.
NCT01300780 ↗	Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching	Completed	Fundação Araucária	N/A	2010-04-01	Perhaps the use of a more selective anti-inflammatory drug, capable of inhibiting enzyme specific for pain may be more effective in preventing the tooth sensitivity caused by the inflammatory response produced by in-office bleaching. To the extent of the authors´ knowledge, no study has so far addressed the use of a selective anti-inflammatory drug specific for pain enzyme on tooth sensitivity, being this the aim of the present investigation.
NCT01300780 ↗	Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching	Completed	Universidade Estadual de Ponta Grossa	N/A	2010-04-01	Perhaps the use of a more selective anti-inflammatory drug, capable of inhibiting enzyme specific for pain may be more effective in preventing the tooth sensitivity caused by the inflammatory response produced by in-office bleaching. To the extent of the authors´ knowledge, no study has so far addressed the use of a selective anti-inflammatory drug specific for pain enzyme on tooth sensitivity, being this the aim of the present investigation.
NCT01300780 ↗	Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching	Completed	Eloisa Andrade de Paula	N/A	2010-04-01	Perhaps the use of a more selective anti-inflammatory drug, capable of inhibiting enzyme specific for pain may be more effective in preventing the tooth sensitivity caused by the inflammatory response produced by in-office bleaching. To the extent of the authors´ knowledge, no study has so far addressed the use of a selective anti-inflammatory drug specific for pain enzyme on tooth sensitivity, being this the aim of the present investigation.

Clinical Trial Conditions for COLGATE TOTAL

Condition Name

Condition Name for COLGATE TOTAL
Intervention	Trials
Gingivitis	5
Dental Plaque	3
Periodontal Disease	2
Dentin Sensitivity	2

Condition MeSH

Condition MeSH for COLGATE TOTAL
Intervention	Trials
Gingivitis	8
Hypersensitivity	6
Dentin Sensitivity	6
Dental Plaque	4

Clinical Trial Locations for COLGATE TOTAL

Trials by Country

+

−

Trials by Country for COLGATE TOTAL
Location	Trials
United States	8
Brazil	6
Iraq	3
India	2
Pakistan	2

Trials by US State

+

−

Trials by US State for COLGATE TOTAL
Location	Trials
North Carolina	2
California	2
Florida	2
New Jersey	1
Indiana	1

Clinical Trial Progress for COLGATE TOTAL

Clinical Trial Phase

Clinical Trial Phase for COLGATE TOTAL
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	6
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for COLGATE TOTAL
Clinical Trial Phase	Trials
Completed	22
Not yet recruiting	4
Unknown status	2

Clinical Trial Sponsors for COLGATE TOTAL

Sponsor Name

Sponsor Name for COLGATE TOTAL
Sponsor	Trials
Colgate Palmolive	12
Dr Meru S	2
University of North Carolina, Chapel Hill	2

Sponsor Type

Sponsor Type for COLGATE TOTAL
Sponsor	Trials
Other	28
Industry	13

Colgate Total: Clinical Trials, Market Analysis, and Projections

Introduction to Colgate Total

Colgate Total is a widely recognized toothpaste and mouthwash brand known for its advanced oral care benefits. Recently, it has been at the forefront of clinical research, particularly in the context of its efficacy against viruses and its impact on oral and systemic health.

Clinical Trials Overview

Laboratory Studies on COVID-19

In 2020, Colgate conducted laboratory studies that showed Colgate Total toothpaste and mouthwashes could neutralize 99.9% of the SARS-CoV-2 virus after two minutes of contact. These studies were part of a broader clinical research program aimed at exploring the potential of oral health products in reducing the spread of COVID-19[1].

Clinical Investigation on Periodontal Disease

A clinical trial, initiated in 2015, focused on evaluating the effects of Colgate Total toothpaste with triclosan compared to a triclosan-free placebo on periodontal disease and systemic inflammatory markers. This Phase 4 interventional study involved subjects aged 18-50 years and assessed periodontal parameters and systemic inflammatory markers over a 12-month period[4].

Key Findings from Clinical Trials

Efficacy Against COVID-19

The laboratory studies demonstrated that Colgate Total toothpaste and certain mouthwashes (Colgate Total, Colgate Peroxyl, and Colgate PerioGard) could significantly reduce the viral load in the mouth, suggesting a potential role in mitigating the spread of COVID-19[1].

Impact on Periodontal Disease

The clinical trial on periodontal disease aimed to assess the effects of Colgate Total toothpaste on markers of inflammation in the bloodstream and periodontal health. The study measured parameters such as periodontal pocket depth and clinical attachment loss, as well as systemic inflammatory markers like CRP, PGE2, IL-1β, and TNF-α. While the full results are not yet published, the study's design indicates a thorough investigation into the toothpaste's anti-inflammatory and periodontal health benefits[4].

Market Analysis

Global Market Share

Colgate Total continues to dominate the global toothpaste market, with Colgate maintaining a 41.6% global market share in toothpaste and 32.3% in manual toothbrushes as of the third quarter of 2024[5].

Sales Performance

In the fourth quarter and full year of 2023, Colgate reported significant sales growth, with net sales and organic sales increasing by 7.0% and 8.5%, respectively. This growth underscores the strong market demand for Colgate's oral care products, including Colgate Total[2].

Market Projections

Growth Trends

The oral care market, driven by increasing consumer awareness of health and hygiene, is expected to continue growing. Colgate's commitment to innovation and clinical research, as seen with Colgate Total, positions the company well for sustained market leadership.

Financial Guidance

For the full year 2024, Colgate has updated its financial guidance, reflecting continued confidence in its sales and profitability. The company's strong gross profit margin and net cash provided by operations indicate a robust financial foundation to support further research and market expansion[5].

Industry Context

Clinical Trials Market

The global clinical trials market, which includes trials for various therapeutic areas, is projected to grow from $48.2 billion in 2023 to $73.2 billion by 2028, at a CAGR of 8.7%. This growth is driven by increasing investments in pharmaceutical R&D and the rising number of drugs in the pipeline[3].

Expert Insights

"We’re at the early stages of our clinical investigations, but our preliminary laboratory and clinical results are very promising," said a spokesperson from Colgate, highlighting the company's commitment to scientific research and its potential impact on public health[1].

Consumer Impact

The clinical trials and market performance of Colgate Total have significant implications for consumers. Here are a few key points:

• Enhanced Oral Health: Colgate Total's proven efficacy in reducing viral loads and improving periodontal health offers consumers a reliable option for maintaining good oral hygiene.
• Market Trust: The brand's strong market share and consistent sales growth reflect consumer trust and satisfaction with the product.
• Innovation: Colgate's ongoing investment in clinical research ensures that consumers have access to innovative products that address emerging health challenges.

Key Takeaways

• Clinical Efficacy: Colgate Total has shown significant efficacy in neutralizing the SARS-CoV-2 virus and improving periodontal health.
• Market Leadership: Colgate maintains a strong global market share in toothpaste and manual toothbrushes.
• Financial Performance: The company has reported robust sales growth and financial performance.
• Industry Growth: The clinical trials market and oral care market are expected to grow significantly in the coming years.
• Consumer Benefits: Consumers benefit from Colgate Total's proven health benefits and the company's commitment to innovation.

FAQs

Q: What were the findings of the laboratory studies on Colgate Total and COVID-19?

A: The laboratory studies showed that Colgate Total toothpaste and certain mouthwashes could neutralize 99.9% of the SARS-CoV-2 virus after two minutes of contact[1].

Q: What is the focus of the clinical trial on Colgate Total and periodontal disease?

A: The clinical trial evaluates the effects of Colgate Total toothpaste on periodontal disease and systemic inflammatory markers over a 12-month period[4].

Q: What is Colgate's global market share in toothpaste?

A: As of the third quarter of 2024, Colgate maintains a 41.6% global market share in toothpaste[5].

Q: How has Colgate's sales performance been in recent years?

A: In the fourth quarter and full year of 2023, Colgate reported a 7.0% and 8.5% increase in net sales and organic sales, respectively[2].

Q: What is the projected growth rate of the global clinical trials market?

A: The global clinical trials market is projected to grow at a CAGR of 8.7% from 2023 to 2028[3].

Sources

1. Colgate Laboratory Tests Show Toothpaste and Mouthwash Neutralize 99.9% of the Virus That Causes COVID-19. Colgate-Palmolive Investor Relations.
2. Colgate Announces 4th Quarter and Full Year 2023 Results. Colgate-Palmolive Investor Relations.
3. Clinical Trials Market Size, Share, Trends and Revenue Forecast. MarketsandMarkets.
4. Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers. ClinicalTrials.gov.
5. Colgate Announces 3rd Quarter 2024 Results. Colgate-Palmolive Investor Relations.